Key facts
- Yemaachi Biotech’s last known valuation is $1.8M (Aug 2021).
- It has raised $5.1M; the latest was Early Stage VC ($2.0M) in Dec 2024.
- Notable investors include Y Combinator, Gates Foundation, Life Line Financial Group, AAIC Investment, Delwik Group — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Yemaachi Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Yemaachi Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Yemaachi Biotech
Developer of a precision oncology platform designed to build a genetically diverse cancer knowledge base and advance inclusive precision medicine. The company offers a pan-African clinical network, high-throughput sequencing, bioinformatics, and a continent-wide cancer atlas initiative, enabling global pharmaceutical companies, diagnostic developers, and biomedical researchers to identify actionable genomic targets that improve drug discovery and cancer diagnostics across diverse populations.
- Sector
- Healthcare
- HQ
- Accra, Ghana
- Founded
- 2020
- Employees
- 45
- Website
- yemaachi.com/
- Ownership
- Privately Held (backing)
Yemaachi Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Yemaachi Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Yemaachi Biotech in its N-PORT filings yet. We sweep new filings monthly.